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Abstract
Tetherin is a membrane protein of unusual topology expressed from rodents to humans that accumulates enveloped virus
particles on the surface of infected cells. However, whether this ‘tethering’ activity promotes or restricts retroviral spread
during acute retrovirus infection in vivo is controversial. We report here the identification of a single nucleotide
polymorphism in the Tetherin gene of NZW/LacJ (NZW) mice that mutated the canonical ATG start site to GTG. Translation
of NZW Tetherin from downstream ATGs deleted a conserved dual-tyrosine endosomal sorting motif, resulting in higher cell
surface expression and more potent inhibition of Friend retrovirus release compared to C57BL/6 (B6) Tetherin in vitro.
Analysis of (B66NZW)F1 hybrid mice revealed that increased Tetherin cell surface expression in NZW mice is a recessive trait
in vivo. Using a classical genetic backcrossing approach, NZW Tetherin expression strongly correlated with decreased Friend
retrovirus replication and pathogenesis. However, the protective effect of NZW Tetherin was not observed in the context of
B6 Apobec3/Rfv3 resistance. These findings identify the first functional Tetherin polymorphism within a mammalian host,
demonstrate that Tetherin cell surface expression is a key parameter for retroviral restriction, and suggest the existence of a
restriction factor hierarchy to counteract pathogenic retrovirus infections in vivo.
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Introduction
In order to infect and persist in the host, retroviruses such as
HIV-1 encode proteins that counteract innate resistance genes that
are also referred to as ‘‘restriction factors’’. Host restriction factors
have the potential to directly interfere with specific steps of the
retrovirus life cycle and have been the subject of intense study in
the last decade. In this regard, mechanistic studies on how the
HIV-1 Vpu protein promotes virion release in vitro resulted in the
discovery of the long-sought ‘Tetherin’ molecule [1–2]. Tetherin
(also known as BST-2, CD317, HM1.24 and PDCA-1) is a
homodimeric protein containing an N-terminal transmembrane
and C-terminal glycophosphatidyl inositol anchor [3] that ‘tethers’
virions on the surface of the infected cells, resulting in extensive
virion aggregation [1–2,4–5].
The impact of Tetherin-mediated virion aggregation on
retroviral spread is controversial. In pandemic HIV-1 strains
lacking the human Tetherin antagonist Vpu, surface-tethered
virions associate with the virological synapse, but this interaction
has been reported to both inhibit [6–7] and promote [8] cell-to-
cell virus spread. Human T-Lymphotropic Virus type I [9] and
Feline Leukemia virus [10] were also suggested to utilize human
and feline Tetherin, respectively, for cell-to-cell spread in vitro.I n
contrast, Tetherin-driven retrovirus evolution in the SIV or SHIV
lentivirus infection models [11–12] suggested that Tetherin was an
antiretroviral factor. Resolving these opposing views may require
pathogenic retrovirus infection studies that isolate the Tetherin gene
in vivo.
Recently, a study in Tetherin deficient mice demonstrated that
Tetherin restricts Moloney Murine Leukemia Virus (MLV) and a
pathogenic MLV complex known as LP-BM5 in vivo [13]. In that
study, Interferon-a (IFN-a) induction through poly(I:C) treatment
was required to unmask the activity of Tetherin in newborn mice
infected with Moloney MLV. Moreover, the effect of Tetherin on
LP-BM5 infection of adult mice was not observed until after 8
weeks post-infection, during the chronic stage and when adaptive
immune responses had already developed. In contrast, studies on
mice deficient with another restriction factor, Apobec3, revealed a
significant impact on retrovirus replication and pathogenesis
during the first week of retrovirus infection in both newborn
[14–15] and adult immunocompetent mice [16–18]. Thus, in
contrast to Apobec3, the impact of Tetherin during acute
retrovirus infection appeared to be minimal, suggesting that
Tetherin may not be a potent innate restriction factor in vivo.
Comparison of Tetherin gene sequences from various mamma-
lian hosts revealed high levels of positive selection in Tetherin,
likely reflecting the long-standing genetic conflict between
retroviruses and mammalian hosts [19–20]. We therefore analyzed
Tetherin gene sequences from catalogued inbred mouse strain
genomes, and report here the identification of a single nucleotide
polymorphism (SNP) in Tetherin that significantly increased its
ability to inhibit retroviral replication and pathogenesis in vivo. Due
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cell surface expression is critical for retroviral control. Finally, the
classical backcrossing approach highlighted a specific genetic
context that revealed potent Tetherin activity during acute
retroviral infection in vivo.
Results
A single nucleotide polymorphism in NZW/LacJ mice
results in translation of a truncated Tetherin protein
To investigate if mouse Tetherin harbored polymorphisms in
putative functional domains, we took advantage of catalogued
polymorphisms from multiple inbred mouse strains archived in the
Ensembl database (Figure S1 in Text S1). A mutation from ATG
(Methionine) to GTG (Valine) (dbSNP ID: rs51822354) was found
in the Tetherin start site of NZW/LacJ (NZW) mice. This was
confirmed by sequencing the region from NZW genomic DNA,
but was not detected in C57BL/6 (B6) (Figure 1A) or the closely
related NZB strain (Figure S1C in Text S1).
Since the Tetherin single nucleotide polymorphism (SNP) maps
to the canonical start site, we first determined the translational
efficiencies of B6 versus NZW Tetherin in a cell-free in vitro
translation assay. B6 and NZW Tetherin were amplified from
primary spleen samples and linked to a C-terminal 36FLAG tag.
We hypothesized that since GUG is a highly inefficient
translational initiation codon in mammalian cells [21], down-
stream Methionines at positions 13 and 16 may be used as
alternative start sites. To investigate this possibility, Methionines at
positions 1, 13 and 16 were mutated singly or in combination to
Alanine (GCC) (Figure 1B). T7-promoter containing PCR
amplicons were translated in rabbit reticulocyte lysates and the
resulting Tetherin translation products were evaluated by Western
blot (Figure 1C). As shown in Figure 1D, wild-type B6 and NZW
Tetherin were translated to equivalent levels, demonstrating that
the Tetherin SNP did not affect Tetherin translation levels. In
contrast, Alanine substitutions of NZW Tetherin at Methionine
positions 13 and 16 (NZW M13,16A mutant) completely
abrogated expression (Figure 1D), demonstrating that Valine at
position 1 could not be used for translational initiation.
Downstream Methionines at positions 13 and 16 likely initiated
Tetherin translation since Alanine substitutions of B6 Tetherin at
Methionine position 1 (B6 M1A mutant) and Methionine positions
1 and 13 (B6 M1,13A mutant) still resulted in translation
(Figure 1D). Translation from downstream Methionines would
result in an approximate 1.4 kDa decrease in molecular weight.
We observed slight shifts in molecular weight between B6 WT,
M1A and M1,13A Tetherin, as well as between NZW WT, M13A
and M16A Tetherin (Figure 1D) that corresponded to translation
products from remaining start sites. Overall, these findings
indicated that NZW Tetherin is translated from downstream
Methionines and lacked the N-terminal 12 amino acids (Figure 1E).
Higher cell surface expression of NZW Tetherin due to
the loss of a critical endosomal sorting motif
The N-terminal cytoplasmic domain of mammalian Tetherins
encodes a conserved dual-Tyrosine motif at amino acid positions 6
and 8 that is critical for clathrin-mediated endocytosis [22–23].
Substituting Tyrosines at positions 6 and 8 of Tetherin with
Alanines (Y6,8A mutant) decreased the internalization of Tetherin
thereby increasing Tetherin cell surface expression [22–24]. Thus,
deletion of the N-terminal 12 amino acids of B6 Tetherin as
predicted for NZW Tetherin (Figure 1D) should increase cell
surface expression. To test this hypothesis, untagged B6 and NZW
Tetherin constructs were transfected into 293T cells and cell
surface expression was analyzed. Using immunofluorescence
microscopy, we observed brighter and more defined signals for
NZW Tetherin on the plasma membrane compared to B6
Tetherin (Figure S2 in Text S1). To quantify cell surface
expression, we performed flow cytometry (Figure 2A), measuring
both median fluorescence intensity (MFI) and percentage of
Tetherin
+ cells. The percentage of Tetherin
+ cells was gated based
on a FI cut-off that yielded ,1% positivity from cells transfected
with empty vector. As expected, NZW Tetherin was expressed to a
significantly higher level on the surface of transfected 293T cells
compared to B6 Tetherin (Figure 2A). In fact, NZW Tetherin was
expressed to a similar extent as the B6 Tetherin endocytosis
mutant Y6,8A and a B6 Tetherin mutant with the canonical start
site mutated to Alanine (M1A) (Figure 2B).
We next compared the total and cell surface levels of B6 and
NZW Tetherin by staining transfected 293T cells in an intact (cell
surface only) versus permeabilized (cell surface plus intracellular)
state. For the same transfected cells, the percentage of Tetherin
+
cells was higher in permeabilized versus intact cells (Figure 2C),
suggesting that a proportion of Tetherin is found inside the cells.
Using the ratio of surface versus total Tetherin expression to
compute intracellular levels, a significantly higher percentage of
B6 Tetherin was found intracellularly compared to NZW Tetherin
(Figure 2D) and the B6 M1A and B6 Y6,8A mutants (Figure S3 in
Text S1), consistent with more efficient endocytosis of B6
Tetherin. Since the total and cell surface Tetherin expression
was higher in NZW Tetherin compared to B6 Tetherin (Figure 2C)
despite no difference in translation efficiencies (Figure 1D), we
hypothesized that B6 Tetherin may be more efficiently shuttled
into endosomal compartments for degradation, as suggested by
other reports [24–25]. We therefore treated B6 Tetherin-
transfected cells with increasing doses of a dynamin-dependent
endocytosis inhibitor, Dynasore [26]. Dynasore treatment restored
B6 Tetherin cell surface expression to similar levels as NZW
Tetherin (Figure 2E; Figure S4 in Text S1). To complement these
results, we also utilized a dominant-negative dynamin mutant,
K44A, that was previously shown to block an intermediate stage in
coated vesicle formation likely due to decreased guanine-
nucleotide binding affinity [27]. Co-expression of B6 Tetherin
with Dynamin K44A [28] increased B6 Tetherin cell surface
expression to the same level as NZW Tetherin (Figure S5 in Text
Author Summary
Significant portions of the human and mouse genomes are
comprised of retroviral sequences, revealing the long
history of conflict between mammalian hosts and retrovi-
ruses that led to the evolution of host restriction factors.
Nucleotide mutations in restriction factor genes provide a
glimpse of this ongoing evolutionary process, but studies
that directly probe the impact of restriction factor
mutations during retrovirus infection are limited. In this
study, we identified a single nucleotide mutation in the
Tetherin host restriction gene that resulted in retention of
Tetherin on the cell surface. In cell culture, Tetherin
accumulates virions on the infected cell surface and
prevents virion release, but some studies suggested that
Tetherin might facilitate cell-to-cell virus spread. Our
studies reveal that the Tetherin polymorphism inhibits
retrovirus replication and disease. Thus, increased Tetherin
cell surface expression enhanced the antiretroviral func-
tion of Tetherin. These results could have important
implications in harnessing the biology of Tetherin for
controlling pathogenic retroviruses such as HIV-1.
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cell surface consistent with deletion of the N-terminal 12 amino
acid domain and the consequent defect in endosomal recycling.
NZW Tetherin more potently inhibited retrovirus release
than B6 Tetherin in vitro
In cell culture, Tetherin activity results in aggregation of
retrovirus particles on the infected cell surface, resulting in
decreased virion release in the surrounding media [1–2,4–5].
Tethering of murine retroviruses by mouse Tetherin has yet to be
visualized, but this is highly likely based on the ability of mouse
Tetherin to tether HIV-1 as observed by electron microscopy [5]
and inhibit the release of Moloney Murine Leukemia Virus [29].
We therefore compared the ability of B6 versus NZW Tetherin to
inhibit the release of Friend Murine Leukemia Virus (F-MuLV).
An F-MuLV molecular clone was co-transfected with untagged
mouse Tetherin constructs into 293T cells and the levels of total
and infectious virions released after 2 days were measured by
quantitative PCR and focal infectivity assays, respectively [30–31].
Between 23 to 34% of co-transfected 293T cells expressed FV
envelope gp70 based on FACS staining following permeabilization
(Figure 3A). Relative to vector control, NZW Tetherin inhibited
total virion release 44-fold, while B6 Tetherin inhibited 11-fold
(Figure 3B). Infectious virion release was inhibited 50-fold for
NZW Tetherin and 17-fold for B6 Tetherin (Figure 3C). The 3 to
4-fold difference in B6 versus NZW Tetherin virion release were
statistically-significant (Figure 3B–C). Moreover, the B6 M1A and
B6 Y6,8A mutants, which exhibited higher cell surface expression
(Figure 2B), also inhibited F-MuLV virion release better than wild
type B6 Tetherin (Figure 3B–C). Since Tetherin has been reported
to decrease HIV-1 virion infectivity [32], we estimated the
infectivity of released F-MuLV virions by calculating the ratio of
non-log transformed infectious titers and viral loads, and
normalized to vector controls [31]. A moderate reduction in
virion infectivity was observed with Tetherin co-transfection but
did not reach statistical significance (Figure 3D). Overall, our
results demonstrated that NZW Tetherin, which is retained on the
cell surface to a greater degree than B6 Tetherin, was a more
potent inhibitor of F-MuLV virion release than B6 Tetherin in
vitro.
Increased Tetherin cell-surface expression in NZW mice is
a recessive trait in vivo
Previous studies have shown that Tetherin dimers are the
functional units critical for restricting virion release in vitro [4,33].
Thus, if B6 and NZW Tetherin heterodimers are formed, the
endocytosis motif in B6 Tetherin could lead to decreased cell
surface expression of the heterodimer. In support of this notion,
co-transfection of B6 and NZW Tetherin at an equimolar ratio led
to cell-surface expression that was similar to B6 Tetherin
(Figure 4A; Figure S6 in Text S1). To extend this finding in vivo,
Tetherin cell surface expression in splenocytes of B6, NZW and
Figure 1. A Tetherin SNP in NZW mice results in truncation of the N-terminal cytoplasmic domain. (A) Sequence analysis of B6 versus
NZW Tetherin. The canonical Tetherin ATG (Methionine) start site in B6 mice is mutated to GTG (Valine) in NZW mice, as shown by the sequence
chromatogram peaks. (B) Tetherin ATG mutant panel. Tetherin ATG sites were mutated to GCC (Alanine) in various combinations and linked to a C-
terminal 36FLAG tag. The mutant names indicated on the left were used in subsequent figure panels. (C) In vitro translation assay. T7-promoter
containing PCR amplicon cassettes were subjected to in vitro transcription/translation in rabbit reticulocyte lysates and analyzed by Western blot. (D)
Translation efficiency of Tetherin mutants. Wild-type B6 and NZW Tetherin were translated at equivalent levels. Expression of the B6 M1A and M1,13A
mutants suggested that Methionines at positions 13 and 16 could initiate translation. The absence of NZW M13,16A expression indicated that Valine
at position 1 in NZW Tetherin could not initiate translation. The slight shifts in molecular weight qualitatively correspond to translation from
remaining Methionine start sites. (E) Model of B6 versus NZW Tetherin. Due to translation from downstream Methionines, NZW mice encode a
Tetherin protein that lacks the first 12 amino acids that contain the dual-Tyrosine (YxY) endosomal sorting motif. WT, wild-type.
doi:10.1371/journal.ppat.1002596.g001
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expressed to significantly higher cell surface levels in NZW mice
compared to B6 mice on dendritic cells and B cells (Figure 4C and
Figure S7A in Text S1) which normally express Tetherin [34–35].
In addition, higher cell surface expression levels of Tetherin were
observed in erythroblasts of NZW compared to B6 mice (Figure 4D
and Figure S7B in Text S1). Importantly, Tetherin cell surface
expression in hybrid (B66NZW)F1 mice was similar to that of B6
mice (Figure 4B–D; Figure S7A–B in Text S1), indicating that
reduced B6 Tetherin cell surface expression was dominant over
NZW Tetherin in vivo.
The recessive Tetherin SNP in NZW mice significantly
inhibits retroviral infection and pathogenesis in vivo
The finding that low cell surface expression of B6 Tetherin was
dominant over the high cell surface expression of NZW Tetherin
provided the opportunity to investigate the effects of Tetherin cell
surface expression levels on retroviral pathogenesis. Mice were
infected with Friend retrovirus (FV) complex, one of the few
retroviruses that cause disease in adult immunocompetent mice,
and for which extensive information on the genetics of host
resistance and susceptibility has been generated [36] (Table 1).
[(B66NZW)F16NZW]B1 offspring were generated, of which half
were expected to be Tetherin
Val/Val (high-surface expressors) and
half Tetherin
Met/Val (low-surface expressors) (Figure 5A). The
impacts of Fv1 [37] and Fv2 [38] host restriction factors (Table 1)
were nullified by infecting with a dual (NB)-tropic FV strain and
by backcrossing to Fv2 dominant susceptible NZW mice,
respectively. In addition, individual mice were genotyped for H-
2, which controls T and B cell immunity [36] (Figure S8A in Text
S1), and for Rfv3, which restricts FV during acute infection,
promotes recovery from viremia, influences neutralizing antibody
responses and is encoded by Apobec3 [17,30] (Figure S8B in Text
S1). B1 mice (n=58) were classified into 4 groups based on H-2
and Rfv3 genotypes, of which 3 had sufficient sample sizes ($5
mice per cohort) for FV infection studies (Table S1 in Text S1).
To control for the antiviral effects of H-2
b and Rfv3
r alleles
from the B6 genetic background [17,39], we initially focused on
Figure 2. Higher cell surface expression of NZW Tetherin compared to B6 Tetherin in vitro. Untagged Tetherin constructs (500 ng) were
transfected into 293T cells in triplicate and analyzed after 2 days. (A) Representative flow cytometry histogram profile of B6 versus NZW Tetherin.
Higher median fluorescence intensity (MFI) was observed for NZW Tetherin compared to B6 Tetherin. (B) Cell surface expression of Tetherin mutants.
Mutating the B6 Tetherin start site (M1A) or endocytosis motif (Y6,8A) to Alanines resulted in similar cell surface expression as NZW Tetherin. Both MFI
(left panel) and % Tetherin (right panel) levels are shown. (C) Tetherin expression in intact versus permeabilized cells. In both intact and permeabilized
cells, NZW Tetherin was expressed to significantly higher levels than B6 Tetherin. However, % Tetherin expression was higher in permeabilized
compared to intact cells, suggesting that a proportion of Tetherin is located intracellularly. (D) Intracellular Tetherin. The percentages of B6 and NZW
Tetherin found intracellularly were calculated based on 1 minus the ratio of Tetherin levels in intact (cell surface) versus permeabilized (total) 293T
cells multiplied by 100. A higher proportion of B6 Tetherin is expressed intracellularly, consistent with more efficient endocytosis. Inhibition of
Tetherin endocytosis in vitro. (E) Treatment of B6 Tetherin transfected cells with an endocytosis inhibitor, Dynasore, resulted in similar cell surface
levels as NZW Tetherin. Mean values from triplicate measurements, standard deviations as error bars and p values from a 2-tailed Student’s t-test are
shown.
doi:10.1371/journal.ppat.1002596.g002
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Table S1 in Text S1). Susceptible Rfv3
s/s H-2
z/z mice were
infected with NB-tropic FV and at 7 days post-infection (dpi),
plasma, spleen and bone marrow samples were analyzed.
Similar to other viral infections [33,40], Tetherin expression
was highly upregulated following FV infection. Splenocyte
Tetherin expression increased from 5-11% Tetherin
+ spleno-
cytes in uninfected NZW and (B66NZW)F1 mice (Figure 5B,
left panel) to 58–87% at 7 dpi (Figure 5B, right panel). In fact,
in mice with acute FV infection, FV positive cells showed
significantly higher Tetherin cell surface expression compared
to FV negative cells (Figure 5C). Interestingly, FV infected
Tetherin
Met/Val mice still exhibited significantly lower Tetherin
cell surface expression in splenic erythroblasts, dendritic cells
a n dBc e l l sa sc o m p a r e dt oTetherin
Val/Val mice, consistent with
their genotypes (Figure 5D).
Figure 3. Higher inhibition of virion release by NZW Tetherin versus B6 Tetherin in vitro. (A) Cellular FV infection levels. Co-transfection of
an infectious F-MuLV molecular clone (1 mg) and Tetherin constructs (50 ng) revealed significant cellular FV envelope gp70 expression by flow
cytometry of permeabilized cells following staining with MAb 720. (B) Total virion release measured by quantitative PCR. NZW Tetherin, as well high-
surface expression mutants of B6 Tetherin, more efficiently inhibited total virion release compared to B6 Tetherin in vitro. (C) Infectious viremia
measured by a focal infectivity assay in Mus dunni cells. NZW Tetherin, as well as high-surface expression mutants of B6 Tetherin, more efficiently
inhibited infectious virion release compared to B6 Tetherin in vitro. (D) Virion infectivity. The ratio of infectious titer and viral load was computed and
normalized to vector control. There was a moderate reduction in virion infectivity in some Tetherin co-transfected cells but these differences did not
reach statistical significance. Mean values from triplicate measurements, standard deviations as error bars and p values from a 2-tailed Student’s t-test
are shown.
doi:10.1371/journal.ppat.1002596.g003
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determinants at 7 dpi to determine if pathogenesis phenotypes
correlated with the Tetherin genotype. Tetherin
Met/Val low-expressor
mice exhibited 5-fold higher infectious plasma viremia (Figure 6A)
and 7-fold higher plasma viral loads (Figure 6B) compared to
Tetherin
Val/Val high-expressor mice. There was a significant inverse
correlation between plasma viral load and Tetherin cell surface
expression in splenocytes (Figure 6C), but most significantly with
erythroblast Tetherin MFI levels (Figure 6D). Virion infectivity,
computed from the ratio of infectious viremia and plasma viral
load [31], was not significantly different between the two cohorts
(Figure 6E). Importantly, Tetherin
Met/Val mice had 2-fold higher
levels of FV infection in bone marrow cells (Figure 7A) that
included dendritic cells, erythroblasts and B cells (Figure 7B). FV-
induced proliferation of Ter119
+ erythroblasts, which eventually
leads to splenomegaly and erythroleukemia [37], was also
increased in both the bone marrows and spleens of Tetherin
Met/
Val mice (Figure 7C). In fact, Tetherin
Met/Val mice had 2-fold higher
levels of splenomegaly compared to Tetherin
Val/Val mice
(Figure 7D). These findings demonstrate that the recessive NZW
Tetherin allele significantly inhibited acute FV replication and
pathogenesis in vivo.
NZW Tetherin does not impact retrovirus pathogenesis in
the context of Rfv3 resistance
Several innate retrovirus restriction factors have been identified
in the last decade, but whether these factors operate in a
synergistic manner to inhibit retroviruses in vivo remain unknown.
The classical backcrossing approach provided an opportunity to
investigate Tetherin restriction in the context of Apobec3/Rfv3,a
deoxycytidine deaminase that inhibits infectious viremia during
acute FV infection [17,31]. B6 mice are Rfv3 resistant and express
higher levels of Apobec3 compared to Rfv3 susceptible NZW mice
[41]. Consistent with the dominance of the Rfv3 resistance allele,
B1 mice genotyped as Apobec3/Rfv3
r/s had significantly lower
infectious viremia at 7 dpi compared to Apobec3/Rfv3
s/s mice
(Figure 8A). Apobec3/Rfv3
r/s mice were further genotyped as
Tetherin
Met/Val or Tetherin
Val/Val, and infectious viremia (Figure 8B),
Figure 4. B6 Tetherin cell surface expression is dominant over NZW Tetherin in vivo. (A) Cell surface expression of putative B6:NZW
heterodimers in vitro. Equimolar transfection of B6 and NZW Tetherin resulted in similar cell surface expression as B6 Tetherin in vitro. (B) FACS gating
strategy. Splenocytes from uninfected B6, NZW and (B66NZW)F1 mice were stained with an anti-Tetherin antibody. Representative flow cytometry
plots showing isotype controls used for gating are shown. (C) Tetherin expression in CD11c
+ dendritic cells. (D) Tetherin expression in Ter119
+
erythroblasts. Left panel, Tetherin FACS histogram from gated Ter119
+ cells. Right panel, percentage of Tetherin
+ cells. In panels C and D, hybrid
(B66NZW)F1 mice had significantly lower Tetherin cell surface expression compared to NZW mice. Each dot corresponds to one mouse analyzed.
Differences between means were evaluated using a 2-tailed Student’s t-test.
doi:10.1371/journal.ppat.1002596.g004
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(Figure 8D) were compared. None of these parameters were
significantly different between Tetherin
Met/Val versus Tetherin
Val/Val
mice (Figure 8B–D). The Tetherin SNP also did not influence
infectious viremia, splenomegaly and bone marrow erythroblast
levels when Apobec3/Rfv3
r/s mice were analyzed according to their
H-2 haplotypes (Table S1 in Text S1). Thus, the protective effect
of NZW Tetherin during acute FV infection was not observed in
the context of Apobec3/Rfv3 resistance.
Discussion
Despite major progress in elucidating how Tetherin interacts
with retroviral pathogens in vitro, the demonstration of Tetherin as
a potent innate restriction factor in vivo remains controversial. In
fact, several studies suggested that Tetherin could facilitate cell-to-
cell virus spread [8–10]. In this study, we identified a Tetherin SNP
in NZW mice that significantly enhanced Tetherin cell-surface
expression, providing the first significant association between
Tetherin genomic variation and innate retrovirus restriction in vivo.
Interrogating the role of the Tetherin SNP is not feasible with a
straightforward knock-out mouse approach. We therefore utilized
a classical genetic backcrossing approach that takes into account
the major resistance and susceptibility genes mapped in the FV
model [36] and the dominance of the B6 Tetherin cell surface
expression phenotype. Our results revealed a direct correlation
between Tetherin genotype, phenotype, and retroviral restriction.
These backcross results excluded contributions by any gene not
closely linked to Tetherin. While genes tightly linked to Tetherin may
still contribute to the resistance phenotype, we argue that this is
unlikely based on several lines of evidence. First of all, the in vivo
restriction phenotype was consistent with the in vitro phenotype of
NZW Tetherin more potently inhibiting FV virion release
compared to B6 Tetherin. Furthermore, there was a strong
correlation between Tetherin cell surface expression levels
mediated by the Tetherin SNP and FV replication in vivo. Finally,
none of the genes flanking Tetherin have previously been identified
as retrovirus restriction factors (Figure S1A in Text S1). It is most
likely that the phenotypes observed were mediated primarily by
the Tetherin SNP.
While this manuscript was being prepared, a study using Tetherin
deficient B6 mice revealed that Tetherin acts as a resistance gene to
counteract Moloney MLV and a pathogenic MLV strain known as
LP-BM5 in vivo [13]. In Moloney MLV infection of newborn mice,
treatment with poly(I:C), a potent inducer of IFN-a, was required
to unmask the antiretroviral activity of Tetherin. On the other
hand, the impact of Tetherin was not observed until after 8 weeks
following pathogenic LP-BM5 infection, a timepoint when IFN-a
was induced, but fits within the chronic stage of infection and
adaptive immune responses. Our results in the FV model were
obtained during acute FV infection (7 dpi) and did not require
exogenous administration of poly(I:C). Interestingly, the FV stock
used in this study, as well as studies that identified the Fv1, Fv2,
Rfv1 and Rfv3 restriction genes and their molecular counterparts
[36], contained Lactate Dehydrogenase-elevating virus (LDV)
[42], a potent inducer of Type I IFNs [43–44]. Thus, our findings
are consistent with the notion that Type I IFN induction is
necessary for Tetherin antiretroviral activity in vivo. However, our
findings differ from [13] in that Type I IFN induction was not
sufficient to reveal the antiviral effect of Tetherin. Even with LDV
Table 1. Known genes that differentially govern acute FV infection in B6 versus NZW mice.
Gene: B6 NZW (B66NZW)F1 (F16NZW) Remarks
Phenotype B1
Fv1: b/b n/n n/b 50% n/n Infection with an NB-tropic
strain nullifies the effect of
Fv1 alleles.
50% n/b
N-tropic FV resistant susceptible resistant
B-tropic FV susceptible resistant resistant
NB-tropic FV susceptible susceptible susceptible
Fv2: r/r s/s r/s 100% Fv2
s is dominant. Thus, all B1
mice should develop
splenomegaly.
Fv2
s
Splenomegaly No Yes Yes
Rfv1 (H-2): b/b z/z b/z 50% z/z CD8 T cell responses,
particularly for H-2
b mice,
are detectable by 6 dpi.
50% b/z
Cell-mediated Immunity High Unknown Unknown
Rfv3 (Apobec3): r/r s/s r/s 50% r/s Rfv3 controls recovery from
viremia and neutralizing
antibody responses. The
effects on acute viremia
were discovered when Rfv3
was identified as Apobec3.
50% s/s
Acute Infectious Viremia (7 dpi) Low High Low
doi:10.1371/journal.ppat.1002596.t001
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protective effect of NZW Tetherin was not observed in the context
of B6 Apobec3/Rfv3 resistance. Thus, Apobec3 is dominant and
not additive with Tetherin restriction in vivo. We hypothesize that
in addition to the lack of Type I IFN induction, the presence of a
potent B6 Apobec3 gene could explain the weak antiviral effect of
B6 Tetherin observed in acute Moloney MLV and LP-BM5
infections [13]. Follow-up studies on Tetherin retrovirus restriction
will likely be more informative in Rfv3 susceptible genetic
backgrounds.
We speculate that the lack of synergy between B6 Apobec3
and NZW Tetherin could be due to mechanistic incompatibility:
Apobec3 activity results in the release of non-infectious virions
[31], while Tetherin activity prevents virion release [1–2]. This
model mirrors restriction factor hierarchies that have been
observed in the FV model. For example, Fv1 is dominant over
Fv2 (a B-tropic virus will not efficiently infect Fv2 susceptible
mice that are Fv1
n/n), while Fv2 is dominant over Rfv3 (Fv2
resistant B6 mice lacking Apobec3 are expected to recover). The
current study suggests the existence of pathways that cross-
Figure 5. Classical backcrossing strategy to analyze the impact of a Tetherin SNP in vivo. (A) Mouse backcrossing strategy. Susceptible
Rfv3
s/s H2
z/z mice from a B1 backcross were genotyped as Tetherin
Val/Val (‘high-Tetherin’ expressors; n=7) or Tetherin
Met/Val (‘low-Tetherin’ expressors;
n=5). The mice were infected with 500 SFFU of NB-tropic FV and biological samples were analyzed at 7 dpi. (B) Induction of Tetherin expression
during acute FV infection. The percentage of Tetherin
+ cells was significantly lower in uninfected (left panel) versus FV infected (right panel) mice. (C)
Increased Tetherin expression in FV infected splenocytes. Left panel,F V + versus FV- cells from infected mice were gated based on reactivity to anti-FV
envelope gp70 antibody (MAb 720) and Tetherin MFI levels from each gate were compared. Right panel, MAb720+ cells showed significantly higher
Tetherin MFI levels compared to MAb720- cells. (D) Tetherin MFI levels in FV susceptible cell types. Infected Tetherin
Val/Val mice exhibited significantly
higher Tetherin expression compared to Tetherin
Met/Val mice in CD11c
+ dendritic cells, Ter119
+ erythroblasts and CD19
+ B cells. Each dot corresponds
to one mouse analyzed. Differences between means were evaluated using a 2-tailed Student’s t-test.
doi:10.1371/journal.ppat.1002596.g005
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in vivo.
The finding that NZW Tetherin is a more potent inhibitor of
FV infection than B6 Tetherin suggests that high cell surface
expression is a key parameter for Tetherin retroviral restriction in
vivo. This result may be unexpected if Tetherin is viewed
primarily as a restriction factor since NZW Tetherin has lost
the YxY endocytosis motif that is present in most mammalian
Tetherins [20]. Thus, from an evolutionary standpoint, Tetherins
with a functional YxY motif should be a more effective
configuration for retroviral restriction in vivo if this restriction is
its primary function. However, Tetherin (or PDCA-1) is a marker
of plasmacytoid dendritic cells (pDC) and may have biological
functions independent of retroviral restriction, such as the
transport of cytokines [34] and regulating the Type I interferon
response [45]. Thus, the Tetherin endocytosis motif may have
been conserved for these physiological functions and retroviral
restriction is part of a dual function. Surprisingly, Tetherin
deficient mice did not harbor perturbations in pDC function
[13]. Further analysis of congenic mice with a canonical (B6),
NZW and null Tetherin may yet uncover critical physiological
roles for Tetherin in vivo.
Studies implicating Tetherin as a modulator of cell-to-cell
spread [8–10] predict that the higher cell-surface expression of
NZW Tetherin should enhance virological synapse formation,
retroviral cellular spread and pathogenesis. Moreover, a study
demonstrating that Tetherin shuttles virions into endosomal
compartments for degradation [25] predict that NZW Tetherin
should have weaker antiretroviral activity. Reconciling these
studies with our seemingly contradictory results will require
tracking the fate of Tetherin-restricted FV virions in congenic
mice encoding B6 versus NZW Tetherin. However, we note that
most studies on Tetherin were performed in vitro, under conditions
that lack immune mediators that are present in vivo. Aggregation of
protein antigens has been known to improve vaccine immunoge-
nicity [46], and Tetherin mediated aggregation of viral particles
may confer a similar effect. The ability of a retrovirus restriction
factor to promote immune responses is not unprecedented:
noninfectious particle release due to B6 Apobec3 activity primed
a more effective IgG response directed against intact virions [31].
Future investigations should therefore determine whether cells
expressing surface-tethered virion aggregates are more efficiently
targeted for innate immune killing and whether NZW Tetherin
activity could prime a more effective adaptive immune response.
Figure 6. NZW Tetherin inhibits acute FV replication in vivo. Susceptible Rfv3
s/s H2
z/z mice were infected with FV and 7 dpi plasma samples
were analyzed against Tetherin genotype. (A) Infectious plasma viremia, as measured using a focal infectivity assay. (B) Plasma viral load, as measured
by quantitative real-time PCR. In panels A and B, high-Tetherin expressing mice had significantly lower levels of infectious viremia and plasma viral
load. (C) Inverse correlation between Tetherin MFI levels in total splenocytes and plasma viral load. (D) Inverse correlation between Tetherin MFI
levels in erythroblasts and plasma viral load. In panels C and D, values were obtained using Pearson product-moment correlation analysis. The inverse
correlation between plasma viral load and Tetherin erythroblast MFI was more statistically significant than with plasma viral load and Tetherin total
splenocyte MFI. (E) Virion infectivity. The ratio of infectious viremia and plasma viral load were compared. No significant differences were obtained.
Each dot corresponds to one mouse analyzed. Differences between means were evaluated using a 2-tailed Student’s t-test.
doi:10.1371/journal.ppat.1002596.g006
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Mice strains
C57BL/6J (B6), BALB/cJ and NZW/LacJ mice were pur-
chased from the Jackson Laboratory. All mice were handled in
strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the University of Colorado
Health Sciences Center Animal Care and Use Committee [Permit
Number B-89709(10)1E]. All infections were performed under
isoflurane anaesthesia, and all efforts were made to minimize
suffering.
Cell culture
293T and Mus dunni cells were cultured in DMEM (Mediatech)
containing 10% Fetal Bovine Serum (Gemini) and penicillin/
streptomycin/glutamine (Mediatech).
Construction of mouse Tetherin mutants
Total RNA from B6 and NZW spleens were extracted using the
RNAEasy kit (Qiagen) and cDNAs were synthesized using random
hexamers in the RT
2 EZ First Strand synthesis kit (SA
Biosciences). Mouse Tetherin was amplified using a forward primer
52 bp upstream of the canonical start codon (59- AAGC-
TTGCGGCCGCTAAGGGCGTGGCCTGGAAAGGGT) and a
reverse primer that excludes the stop codon (59-GAATCCTCTA-
GAAAAGAGCAGGAACAGTGACACT). Cloning sites for NotI
and XbaI (italicized) were included in the primer, allowing for
direct subcloning of the PCR amplicon into the p36FLAG-CMV-
14 vector (Sigma). Various Alanine (GCC) mutations were
introduced using the Quikchange XL Mutagenesis Kit (Strata-
gene). A stop codon (TAG) between the last amino acid in Tetherin
and the 36FLAG tag was introduced to prepare untagged versions
of these constructs. All constructs were verified by DNA
sequencing.
Cell-free in vitro translation
T7 expression cassettes were generated from the Tetherin
constructs by PCR amplification with a forward primer
containing the underlined T7 promoter (59- TAATACGACT-
CACTATAGGGTAAGGGCGTGGCCTGGAAAGGGT) and
a reverse primer that flanks the 36FLAG tag. Purified PCR
products (400 ng) were added into 50 ml of rabbit reticulocyte
lysate from the TNT T7 coupled in vitro transcription/
translation kit (Promega) and incubated at 30uCf o r9 0m i n .
5 ml of lysate was solubilized in 50 mlo fL a e m m l ib u f f e r ,a n d
5 ml of solubilized lysate was loaded in a 4–20% gradient
Criterion Gel (Biorad) and transferred into PVDF membranes
(Invitrogen). High levels of reticulocyte proteins below 20 kDa
were cut out of the membrane prior to incubation with
antibodies. Membranes were blocked with 5% skim milk for
2 h, probed with 1:500 dilution of anti-FLAG M2 monoclonal
antibody (Sigma) overnight, washed and incubated with 1:5000
anti-mouse horseradish peroxidase conjugate (Amersham) for
1 h. The blots were developed using the Western Lightning
reagent (Perkin-Elmer) and visualized in a Chemidoc XRS+
system (Biorad). Commercial anti-Tetherin antibodies from
Abnova (catalogue # PAB13047) and Abcam (catalogue #
ab14694) did not detect mouse Tetherin by Western blot
analysis (data not shown).
Figure 7. NZW Tetherin inhibits acute cellular FV replication and pathogenesis in vivo. (A) Bone marrow FV infection levels. FV infected
bone marrow cells were quantified by FACS staining with MAb 720. (B) FV infection of bone marrow cell subsets. MAb 720
+ cells were quantified on
gated CD11c
+ dendritic cells, Ter119
+ erythroblasts and CD19
+ B cells. In panels A and B, high-Tetherin expressing mice showed significantly higher
cellular FV infection levels. (C) Erythroblast percentages. The proportions of Ter119
+ cells from gated live bone marrows (left panel) and spleens (right
panel) were measured. FV pathogenesis is characterized by increased erythroblast proliferation. (D) Splenomegaly, based on wet spleen mass. In
panels C and D, high-Tetherin expressing mice had significantly lower erythroblast percentages and splenomegaly. Each dot corresponds to an
infected mouse. Solid lines correspond to mean values and differences were evaluated using a 2-tailed Student’s t test.
doi:10.1371/journal.ppat.1002596.g007
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Untagged Tetherin expression plasmids (500 ng) were trans-
fected in triplicate into individual wells of a 6-well plate containing
80,000 293T cells using the Fugene 6 reagent (Promega). After 2
days, the cells were washed twice and harvested with 1 ml of
FACS buffer (PBS+2% FBS). Different doses of Dynasore (Sigma)
were added 4 hr before harvest in some experiments. To quantify
total Tetherin expression (cell surface plus intracellular), 293T cells
were permeabilized and stained using the Cytofix/Cytoperm Kit
(BD Biosciences). As an alternative to Dynasore treatment to block
endocytosis, 1 mg of wild-type or K44A mutant dynamin in an
eGFP-expression vector (generously provided by P. De Camilli
through Addgene, plasmids 22163 and 22197; [28]) and 250 ng of
B6 or NZW Tetherin were co-transfected into 293T cells using
Fugene 6. Tetherin expression was analyzed in gated dynamin-
eGFP+ cells. In all cases, 60 ml of the cell suspension was stained
with 0.5 ml of PE-conjugated anti-PDCA-1 (eBioscience; clone
eBio927) for 30 min on ice, washed twice with FACS buffer then
fixed with 1% paraformaldehyde. Samples were analyzed in a
FACSCalibur machine (BD Biosciences), collecting at least 80,000
total events.
Fluorescence microscopy
Untagged Tetherin constructs as well as vector control (100 ng)
were transfected into 293T cells using Fugene 6 in poly-D-Lysine
coated chamber slides (BD Biocoat; BD Biosciences). After 2 days,
the cells were washed with PBS, fixed with 4% paraformaldehyde
then blocked for 1 hr at room temperature with PBS containing
8% normal goat serum and 0.02% Triton X-100 (Sigma). The
samples were stained with 1:100 anti-PDCA1 Alexa-488
(eBioscience) overnight at 4uC. The following day, the cells were
stained with diamidino2-phenylindole (DAPI; Sigma) for 10 min
at room temperature, and then washed 36with PBS. The samples
were visualized in a Zeiss Axioplan2 microscope.
F-MuLV in vitro restriction assay
The F-MuLV molecular clone pLRB302 [47] (1 mg) was co-
transfected in triplicate with 50 ng Tetherin expression constructs
into 6-well plates containing 80,000 293T cells plated the previous
day with Fugene 6 (Promega). After 2 days, MAb 720 supernatant
was used to detect FV envelope gp70 expression by incubating
permeabilized cells for 30 min, followed by 2 washes with FACS
buffer and incubation for 30 min with goat anti-mouse IgG1
Figure 8. B6 Apobec3 is a dominant over NZW Tetherin restriction in vivo. (A) Apobec3/Rfv3 genotype influence acute infectious viremia.
Infectious viremia, as measured using the Mus dunni focal infectivity assay, was measured for the entire B1 cohort (n=58). Apobec3/Rfv3
r/s mice
exhibited significantly lower infectious viremia. Apobec3/Rfv3
r/s mice (n=39) were genotyped as Tetherin
Val/Val versus Tetherin
Met/Val and various FV
infection and pathogenesis parameters were compared. (B) Infectious viremia, split by Tetherin genotype from panel A. (C) Splenomegaly, based on
wet spleen mass. (D) Bone marrow erythroblast percentages, quantified following FACS staining with Ter119 marker. In panels B to D, Tetherin
Val/Val
and Tetherin
Met/Val exhibited similar levels of infectious viremia, spleen mass and bone marrow erythroblast percentages. Each dot corresponds to an
infected mouse. Solid lines correspond to mean values and differences were evaluated using a 2-tailed Student’s t test.
doi:10.1371/journal.ppat.1002596.g008
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2 supernatants were quantified using a focal infectivity assay in
Mus dunni cells with MAb 720 [17]. Total virion titers were
determined using a quantitative real-time PCR based viral load
assay [30–31] from 100 ml of culture supernatant treated with
2.5U DNAseI (Benzonase; EMD Millipore) for 30 min at room
temperature. The same assay was also used to measure plasma
viral load from 50 ml of infected mouse plasma. Quantitative PCR
was performed at least in triplicate and had PCR efficiencies
.90%.
H-2, Apobec3 and Tetherin genotyping
H-2 was genotyped by directly sequencing a 1.0-kb H2-Q1 PCR
fragment amplified using primers H2.F (AACCTGGGT-
CAGGTCCTTCT) and H2.R (CATGGCTGACAGAGGC-
TACA) (Figure S8A in Text S1). To genotype Apobec3/Rfv3,w e
used a multiplex primer set consisting of primers spanning (mA3.F
and mA3.R) and positioned (LTR.F) within a 530 bp retroviral
xenotropic murine leukemia virus (X-MLV) insertion in B6 mice
[30,41] (Figure S8B in Text S1). The primer sequences are: mA3.F
(TTCACAACCCCCATACTTGG); mA3.R (CAGGCTGGTC-
TCAAACGATA); and LTR.F (TTGGGGAACCTGAAACT-
GAG). To genotype the start codon mutation in Tetherin,w e
amplified a 582 bp fragment spanning the start codon using
primers Bst2.F (AAACCTTGGCCTTTGGTCTT) and Bst2.R
(TGTGACGGCGAAGTAGATTG) and directly sequenced the
PCR products using an internal primer Bst2.seq (GCGGACAGC-
CACTGTTAAGT) (Figure S1C in Text S1). Tail DNA samples
(10 ng) were added into a 20 ml PCR reaction consisting of 16
Phusion HF Buffer, 10 mM dNTP, 20 pmol of primers and
1.25 U of Hot Start Phusion polymerase (New England Biolabs).
Cycling conditions in a PE 9700 machine included a 30 s hot-start
at 98uC, followed by 30 cycles of 98uC 10 s denaturation, 60uC
30 s annealing and 72uC 1 min elongation.
FV infection of mice and immunophenotyping
The FV stock used in this study contains an NB-tropic F-MuLV
helper virus, a replication-defective Spleen-Focus Forming Virus
and LDV. LDV is a natural mouse virus endemic in wild mouse
populations, and its presence in the FV stocks has been traced to
the 1960s from naturally infected mice [48–49]. Major findings
that include the identification of Fv1, Fv2, Rfv1 and Rfv3 and their
molecular counterparts utilized LDV+ FV stocks [36,42]. These 4
genes were used to classify and genotype the B1 cohort. Thus, an
LDV+ FV inoculum was essential for this study. LDV was shown
to stimulate Type I IFN production and modulates adaptive
immune responses, but does not significantly influence acute FV
infection levels [42]. FV inoculum stocks were prepared in BALB/
c mice and had equivalent titers in BALB/c and NZW mice (data
not shown). NB-tropic FV (500 SFFU) was infected intravenously
in 300 ml RPMI and at 7 dpi, plasma samples, bone marrows and
spleens were harvested. Due to severe male aggression, infections
were performed in female B1 mice, without prior knowledge of the
Tetherin genotype. Bone marrow and spleen cells (10
6 cells) were
stained with MAb 720 for 30 min, then co-stained with: Ter119-
FITC (clone TER-119), CD3-Alexa700 (17A2), (BD Biosciences);
PDCA-1-PE (eBio927), CD11c-PE-Cy7 (N418), (eBioscience);
CD19-PerCP-Cy5.5 (6D5) (Biolegend) and anti-mouse IgG1-
APC (Columbia Biosciences). Isotype controls and cells from
uninfected mice were used for gating. The multicolor FACS panel
yielded similar data from mice spleen and bone marrow with or
without the addition of a mouse anti-CD16 Fc blocker (BD
Biosciences) (data not shown). Cells were processed in an LSR-II
flow cytometer (BD Biosciences), collecting up to 250,000 events
per sample. Datasets were analyzed using the Flowjo software
(Treestar).
Supporting Information
Text S1 Supporting Figures S1 to S8 and Supporting Table 1
are presented with the corresponding legends.
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